Showing results (311-320 of 1,842) with videos related to
Sort By:
Pageof 185
Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Estimating the Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data from the Rhode Island Prescription Drug Monitoring ProgramHilary Aroke, Ashley Buchanan, Xuerong Wen, et al.Journal of Managed Care & Specialty Pharmacy|February 28, 2018
The Effect of Opioid Use and Mental Illness on Chronic Disease Medication Adherence in SuperutilizersSatya Surbhi, Ilana Graetz, Jim Y Wan, et al.Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Antiepileptic Drug Titration and Related Health Care Resource Use and CostsJesse Fishman, Linda Kalilani, Yan Song, et al.Journal of Managed Care & Specialty Pharmacy|May 26, 2018
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health PlanJonathan Graham, Stephanie Earnshaw, Kate Burslem, et al.Journal of Managed Care & Specialty Pharmacy|June 22, 2017
The Emerging Role of Pimavanserin in the Management of Parkinson's Disease PsychosisNeal Hermanowicz, Gustavo Alva, Fernando Pagan, et al.Journal of Managed Care & Specialty Pharmacy|May 10, 2017
Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart FailureMichael Polson, Todd C Lord, Anne Kangethe, et al.Journal of Managed Care & Specialty Pharmacy|April 26, 2018
Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic StudyMina Tadrous, Mayur Brahmania, Diana Martins, et al.Journal of Managed Care & Specialty Pharmacy|April 26, 2018
The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication UseArmando Silva Almodovar, David Rhys Axon, Ashley M Coleman, et al.Journal of Managed Care & Specialty Pharmacy|May 23, 2017
The Direct Cost of Managing a Rare Disease: Assessing Medical and Pharmacy Costs Associated with Duchenne Muscular Dystrophy in the United StatesSarah Thayer, Christopher Bell, Craig M McDonaldJournal of Managed Care & Specialty Pharmacy|May 23, 2017
Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple SclerosisAnkur A Dashputre, Khalid M Kamal, Gauri PawarPageof 185